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Exposure to methylmercury (MeHg) from 
fish consumption may be associated with an 
increased risk of heart diseases, particularly 
myocardial infarction (Stern 2005). The main 
evidence supporting this relationship was pro-
vided by Finnish studies conducted among 
non-fatty-fish eaters (Salonen et al. 1995). 
Other populations consume different species 
of fish and in some cases marine mammals, 
and their risk of cardiovascular effects may be 
related not only to MeHg exposure but also to 
nutrients that may counteract the toxic effects 
of MeHg, such as omega-3 polyunsaturated 
fatty acids (n-3 PUFAs) and selenium, that are 
high in some marine foods. Inuit populations 
living in circumpolar countries have had lower 
incidences of coronary heart disease (CHD), 
particularly ischemic diseases, than those of 
more southern populations living in indus-
trialized areas (Bang et al. 1971; Corcoran 
and Rabinowitch 1937; Kjaergaard et al. 
2009). However, changes in some aspects 
of their diet and lifestyle that have occurred 
over the last decades have been associated 
with increased risk of CHD (Château-Degat 
et al. 2010; Counil et al. 2009; Jorgensen 
et al. 2008; Young et al. 2007). In particular, 
a decreased intake of food items that are rich 
in n-3 PUFAs or selenium (sea mammal fat 
and skin) could exacerbate the toxic effects of 
MeHg on the cardiovascular system.
The mechanism of action through which 
MeHg increases the risk of CHD remains to 
be identified. Oxidative damage generated by 
MeHg has been suggested as a possible early 
biological effect resulting from MeHg expo-
sure, in turn causing lipid peroxidation, inflam-
mation, and endothelial cell damage (Grotto 
et al. 2009). Animal studies have shown that 
MeHg can induce oxidative stress directly by 
catalyzing reactions that produce reactive oxy-
gen species (Grotto et al. 2009; Lin et al. 2006). 
Alternatively, oxidative stress may indirectly 
result from the interaction of MeHg with thiol 
or selenol groups in antioxidant molecules such 
as glutathione and enzymes such as glutathione 
peroxidase and thioredoxin reductase (Carvalho 
et al. 2008; Khan and Wang 2009).
Human paraoxonase (PON1) is an 
enzyme associated with the high-density lipo-
protein (HDL) particle that inhibits oxidation 
of low-density lipoprotein (LDL) and HDL 
through hydrolysis of lipid peroxides (Aviram 
2000; Mackness et al. 1998). Knockout mice 
lacking the PON1 gene develop atherosclero-
sis more rapidly than do wild-type mice (Shih 
et al. 2000). Hence, it has been suggested that 
PON1 inhibits the atherosclerotic process by 
preventing LDL oxidation in the arterial wall. 
The involvement of PON1 in the pathogenic 
sequence is further supported by the fact that 
decreased PON1 activity is associated with an 
increased prevalence of atherosclerosis (Jarvik 
et al. 2000; Mackness et al. 2001) and incidence 
of cardiovascular disease (Mackness et al. 2003).
Three common single-nucleotide poly-
morphisms (SNPs) within the PON1 gene 
appear to be the strongest determinants of 
serum PON1 activity (Costa et al. 2005; 
Ferré et al. 2003). Two SNPs occur in the 
coding region: the first involves a change of 
methionine (M allele) for leucine (L allele) at 
position 55 (L55M; rs854560); the second 
involves the substitution of arginine (R allele) 
for glutamine (Q allele) at position 192 
(Q192R; rs662). The latter has been shown to 
significantly modulate the activity of PON1 
toward its various substrates. The third SNP, 
–108C/T (rs705379), is located in the pro-
moter region and has a major influence on 
PON1 expression (Brophy et al. 2001).
Despite the predominance of genetic 
influences, several other factors can modu-
late serum PON1 activity, such as age, drugs, 
diseases, smoking, alcohol, diet, and envi-
ronmental chemicals (Costa et al. 2005). 
Because of the known capacity of toxic metals 
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Ba c k g r o u n d: Methylmercury (MeHg) exposure has been linked to an increased risk of coronary 
heart disease (CHD). Paraoxonase 1 (PON1), an enzyme located in the high-density–lipoprotein 
(HDL) fraction of blood lipids, may protect against CHD by metabolizing toxic oxidized lipids 
associated with low-density liproprotein and HDL. MeHg has been shown to inhibit PON1 activ-
ity in vitro, but this effect has not been studied in human populations.
oBjectives: This study was conducted to determine whether blood mercury levels are linked to 
decreased plasma PON1 activities in Inuit people who are highly exposed to MeHg through their 
seafood-based diet.
Me t h o d s : We measured plasma PON1 activity using a fluorogenic substrate and blood concen-
trations of mercury and selenium by inductively coupled plasma mass spectrometry in 896 Inuit 
adults. Sociodemographic, anthropometric, clinical, dietary, and lifestyle variables as well as PON1 
gene variants (rs705379, rs662, rs854560) were considered as possible confounders or modifiers of 
the mercury–PON1 relation in multivariate analyses.
re s u l t s: In a multiple regression model adjusted for age, HDL cholesterol levels, omega-3 fatty 
acid content of erythrocyte membranes, and PON1 variants, blood mercury concentrations were 
inversely associated with PON1 activities [β-coefficient = –0.063; 95% confidence interval (CI), 
–0.091 to –0.035; p < 0.001], whereas blood selenium concentrations were positively associated 
with PON1 activities (β-coefficient = 0.067; 95% CI, 0.045–0.088; p < 0.001). We found no inter-
action between blood mercury levels and PON1 genotypes.
co n c l u s i o n s: Our results suggest that MeHg exposure exerts an inhibitory effect on PON1 activ-
ity, which seems to be offset by selenium intake.
key w o r d s : Inuit, methylmercury, Nunavik, omega-3 polyunsaturated fatty acids, paraoxonase, 
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to inhibit enzymes, in vitro experiments have 
been conducted to investigate the inhibitory 
effects of toxic metals on PON1 activity. 
Gonzalvo et al. (1997) first reported that cop-
per and mercurials were potent inhibitors of 
PON1 activity in human liver microsomes. 
Similar results were obtained in other in vitro 
experiments conducted with pooled human 
serum of subjects with the PON1Q192 geno-
type; manganese (Mn2+), cobalt (Co2+), cad-
mium (Cd2+), and nickel (Ni2+) also inhibited 
PON1 activity in these experiments (Debord 
et al. 2003). Subsequent studies have reported 
that metals were more effective inhibi-
tors of the PON1R192 isozyme than of the 
PON1Q192 isozyme (Cole et al. 2002; Costa 
et al. 2005; Gençer and Arslan 2009). Despite 
these compelling results from in vitro experi-
ments, treatment of mice with Cd, MeHg, or 
dietary iron, leading to metal serum concen-
trations > 1 μM, did not alter serum or liver 
PON1 activity (Cole et al. 2002). To our 
knowledge, the association between MeHg 
exposure and PON1 activity has yet to be 
tested in humans and may prove to be of pub-
lic health relevance in Inuit who are highly 
exposed to MeHg through fish and marine 
mammal consumption (Fontaine et al. 2008). 
This population is also exposed to lead, a 
metal whose blood levels were significantly 
associated with decreased serum PON1 activ-
ity in lead workers (Li et al. 2006).
We conducted a comprehensive health 
survey in the Inuit population of Nunavik 
(Québec, Canada) during the fall of 2004. 
In the course of this study, we investigated 
the relation between blood mercury concen-
trations and plasma PON1 activities in 896 
Inuit adults living in Nunavik, while taking 
into account the potential protective role of 
selenium, which has been shown to coun-
teract the toxicity of mercurials (Khan and 
Wang 2009). We also investigated the pos-
sible confounding or modifying role of several 
factors, including PON1 gene variants.
Materials and Methods
Study population and data collection. This 
health survey was conducted in Nunavik, 
a northern region of Québec where approxi-
mately 9,500 Inuit live in 14 communities 
along the coasts of Hudson Bay, Hudson 
Strait, and Ungava Bay. Informed consent was 
obtained from all participants before enroll-
ing them in the study, which was approved 
by the Comité d’éthique de la recherche de 
l’Université Laval and the Comité d’éthique de 
santé publique du Québec. The target popula-
tion of this study was permanent Inuit residents 
of Nunavik from 18 to 74 years of age. To 
obtain a standard representation of the target 
population, the study used a stratified random 
sampling of private Inuit households, with the 
community being the stratification variable.
Several self-administered and interviewer-
completed questionnaires were used to obtain 
information regarding demographics, lifestyle 
habits, nutrition, and health indicators. In 
addition, individuals were asked to participate 
in a clinical session where blood samples were 
taken and anthropometric measurements were 
performed. Data on body composition (body 
fat percentage, lean body mass) were obtained 
by bioelectrical impedance using the Tanita 
TBF-300A analyzer (Tanita Corporation of 
America, Inc., Arlington Heights, IL, USA). 
Medical history and related drug consump-
tion of each participant were documented by 
medical chart review.
Among the 677 contacted households, 521 
agreed to participate (household response rate 
of 77.8%), 1,056 individuals signed a consent 
form, and 917 people agreed to the collection 
of blood samples for clinical and toxicologi-
cal analy  ses (final participation rate of 67%). 
Because of various problems (insufficient plasma 
volume, broken vials), we measured PON1 
activity for 899 individuals. Three participants 
were excluded from the database because of 
extreme values of blood mercury (> 800 nmol/L) 
and blood selenium (> 30 μmol/L).
Data on the consumption of traditional 
foods were obtained from a food frequency 
questionnaire, which was designed to measure 
season-specific consumption of food items 
derived from fishing and hunting during the 
year before the survey. Season-specific intakes 
were computed by multiplying the daily con-
sumption frequency by the portion size for 
each food item and season. Season-specific 
intakes were then averaged over the four sea-
sons to yield the mean annual consumption 
(grams per day). The following three compos-
ite variables were created: a) wild fish com-
prised clam, mussel, oyster, scallop, seaweed, 
urchin, arctic char, cod, whitefish, trout, 
salmon, dried fish, and other fish such as pike, 
cisco, and walleye; b) marine mammal fat 
comprised beluga and seal fat; and c) marine 
mammal meat comprised beluga meat, dried 
beluga, beluga muktuk (skin), beluga liver, 
other parts of beluga, seal meat, walrus meat, 
igunak (aged meat), seal kidney, seal liver, 
other parts of seal, and walrus parts.
Plasma PON1 activity. Blood was collected 
from a cubital vein in a 6-mL plastic Vacutainer 
containing sodium heparin as the anticoagu-
lant (BD Medical, Mississauga, ON, Canada). 
Blood was centrifuged within 2 hr of collection, 
and the plasma was stored frozen at –80°C 
until time of analysis. Although in most previ-
ous studies PON1 activity has been meas  ured 
in serum samples, the suitability of heparin- 
plasma samples was demonstrated by Ferré 
et al. (2005). PON1 activity was measured in 
5 μL plasma, diluted to a final concentration 
of 2%, using the EnzChek Paraoxonase Assay 
Kit  (Molecular Probes, Invitrogen, Carlsbad, 
CA, USA). This highly sensitive, homogeneous 
fluorometric assay for the organophosphatase 
activity of PON1 is based on the hydrolysis of a 
fluorogenic organophosphate analog (7-diethyl-
phospho-6,8-difluor-methylumbelliferyl). The 
intensity of emitted light was measured with 
a Victor2 plate reader (PerkinElmer–Cetus 
Life Sciences, Boston, MA, USA) using 355- 
and 460-nm filters for excitation and emission, 
respectively. Enzymatic activity was calcu-
lated by converting fluorescence intensity into 
activity using a standard curve. Activity was 
expressed as kilounits per liter, where one unit 
of PON1 is defined as the amount of enzyme 
that produces 1 nmol fluorescent product per 
minute at 37°C. Aliquots of a plasma sample 
obtained from a volunteer were stored frozen 
at –80°C along with the study samples; this 
“control” sample was analyzed in each analyti-
cal batch. The mean value was 13.3 kU/L, and 
the between-day coefficient of variation was 
7.6% (n = 23).
Metal analyses. Mercury, selenium, and 
lead concentrations were determined in whole-
blood samples collected from a cubital vein in a 
6-mL plastic Vacutainer containing potassium 
EDTA as the anticoagulant (BD Medical). 
Blood samples were stored frozen at –80°C 
until time of analysis. Determination was per-
formed by inductively coupled plasma mass 
spectrometry on an ELAN DRC II instrument 
for mercury and selenium and an Elan 6000 
instrument for lead (Perkin-Elmer SCIEX, 
Concord, ON, Canada). Blood samples were 
diluted 20-fold in an ammonia solution before 
analysis. Limits of detection for mercury, lead, 
and selenium were 0.5 nmol/L, 1 nmol/L 
and 0.1 μmol/L, respectively, and each run 
of samples included a standard. Between-day 
coefficients of variation for mercury, lead, and 
selenium measurements were 2.1%, 2.8%, 
and 6.1%, respectively. Analyses were per-
formed by the Laboratoire de Toxicologie 
of the Institut National de Santé Publique 
du Québec, which has ISO 17025 accredita-
tion and participates in the quality assurance/
quality control programs of the Canadian 
Northern Contaminants Program and the 
Arctic Monitoring Assessment Program.
Plasma lipids. Concentrations of total cho-
lesterol and triacylglycerol in plasma samples 
were determined by enzymatic methods using 
a Hitachi 917 autoanalyzer and reagents, both 
from Roche Diagnostics (Laval, QC, Canada). 
HDL cholesterol (HDL-C) was measured 
directly by selectively inhibiting reaction with 
other lipoproteins. LDL cholesterol (LDL-C) 
was calculated using the Friedewald formula 
[LDL-C (grams per liter) = total cholesterol 
(grams per liter) – HDL-C (grams per liter) – 
triacylglycerol (grams per liter)/5] (Tremblay 
et al. 2004). Lipid analyses were performed 
at the Centre de Recherche sur les Maladies 
Lipidiques (Centre de Recherche du Centre MeHg and plasma paraoxonase activity in Inuit
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Hospitalier Universitaire de Québec, Quebec, 
QC, Canada).
Fatty acid analysis in erythrocyte mem-
branes. The fatty acid composition of phos-
pholipids in erythrocyte membranes was also 
determined at the Centre de Recherche sur les 
Maladies Lipidiques. Briefly, total lipids were 
extracted with a chloroform/methanol mix-
ture, and the phospholipid fraction was iso-
lated by thin-layer chromatography (Shaikh 
and Downar 1981). Fatty acids were trans-
methylated (Lepage and Roy 1988), and the 
resulting fatty acid methyl esters were analyzed 
by capillary-column gas chromatography on a 
Hewlett-Packard 5890 series II gas chromato-
graph (Hewlett-Packard, Mississauga, ON, 
Canada) equipped with a fused silica column 
(DB-23; 30 m × 0.25 mm inner diameter 
× 0.25 μm thickness; Agilent Technologies, 
Mississauga, ON, Canada) and a flame ion-
ization detector. Concentrations of individual 
fatty acids in membrane phospholipids were 
expressed as a percentage of total fatty acids 
(weight basis). The sum of eicosapentaenoic 
acid (EPA; 20:5n-3) and docosahexaenoic 
acid (DHA; 22:6n-3) content of erythrocytes 
was used as a surrogate of marine food con-
sumption. This sum has been referred to as 
the omega-3 index and has been shown to be 
inversely associated with risk for CHD mor-
tality (Harris and Von Schacky 2004).
Genotyping. A subsample of 659 partici-
pants gave their consent to the geno  typing 
measures. Variants of rs662, rs854560, and 
rs705379 were originally analyzed using 
Sequenom technology at McGill University 
and Génome Québec Innovation Centre 
(Montréal, QC, Canada). One SNP failed 
(rs705379), and the call rate was > 99.7% for 
the remaining two SNPs. The error rate of this 
technology is < 0.5% according to duplicate 
and control samples tested at the Génome 
Québec Innovation Centre. The rs705379 
SNP was reanalyzed with the TaqMan tech-
nology at the same center with success and a 
call rate of 99.9%. TaqMan technology has 
an average error rate of 0.1%. All genotypes 
were in Hardy–Weinberg equilibrium.
Statistical analyses. To meet normality 
assumption, body mass index (BMI), fat mass, 
blood mercury and lead levels, plasma HDL-C 
and LDL-C concentrations, EPA content of 
erythrocyte membranes, PON1 activity, and 
food consumption rates were log transformed, 
whereas an inverse transformation was retained 
for blood selenium levels. Transformations 
were selected based on both normality test 
(Kolmogorov–Smirnov) and bivariate relation-
ships between variables. We used the BoxCox 
macro developed by Michael Friendly to 
achieve the best transformation (http://www.
datavis.ca/sasmac/boxcox.html). Pearson’s cor-
relation coefficients were used to investigate 
crude relationships between PON1 activity 
(kilounits per liter) and blood concentrations 
of mercury (nanomoles per liter), selenium 
(micromoles per liter) and lead (micromoles 
per liter), age (years), BMI (kilograms per 
square meter), fat mass (kilograms), HDL-C 
(millimoles per liter), LDL-C (millimoles per 
liter), marine food consumption (grams per 
day), and n-3 PUFAs (percent). Student’s 
t-tests or analyses of variance were used to test 
differences in mean PON1 activity according 
to sex, alcohol consumption (daily, weekly, 
monthly, never, or yearly), daily cigarette con-
sumption (0, 1–10, 11–24, ≥ 25), genotypic 
variables (rs705379, rs662, rs854560), sta-
tin intake, cardiovascular diseases, diabetes, 
and dyslipidemia (for disease definitions, see 
Château-Degat et al. 2010). We subsequently 
conducted multiple linear regression analyses 
to examine the relation between blood mercury 
level and plasma PON1 activity, while control-
ling for several potential confounding factors. 
Interactions terms (mercury × PON1 variants, 
mercury × selenium, mercury × n-3 PUFAs) 
were included in initial models. Generalized 
estimating equations techniques were used to 
take into account the clustering structure of 
the data (household was the sampling unit). 
Continuous explanatory variables were also 
centered and scaled for multicollinearity and 
interpretive purposes. Furthermore, because 
of a considerable number of missing values for 
gene variants (27% of participants), multiple 
linear regression analysis was rerun after using 
multiple imputation methods on genotypic 
variables. The Kolmogorov–Smirnov test of 
normality was conducted on regression residu-
als. Contrasts were used to test a linear combi-
nation of mercury quartiles coefficients (trend 
test). Because of the complex design sampling 
and to achieve precision in the parameter 
estimates, statistical tests were weighted and 
bootstrapped (balanced repeated replication). 
All analyses were performed using SUDAAN 
software (version 10.0.1; Research Triangle 
Institute, Research Triangle Park, NC, USA) 
and SAS software (version 9.2; SAS Institute 
Inc., Cary, NC, USA). We selected an α-level 
of 0.05 for hypothesis testing.
Results
Table 1 lists selected characteristics of our 
study group, which is composed of 896 Inuit 
Table 1. Selected characteristics of Inuit adults participating to the Nunavik Health Survey, 2004.
Men Women
Characteristic n Mean (95% CI) n Mean (95% CI)
Age (years) 405 36.5 (35.9–37.0) 491 36.7 (36.2–37.2)
Weight (kg) 380 74.4 (72.8–76.0) 438 65.8 (64.5–67.1)
Height (cm) 390 166.1 (165.5–166.7) 447 153.9 (153.6–154.4)
BMI (kg/m2) 380 26.9 (26.4–27.4) 438 27.7 (27.2–28.2)
Fat mass (kg) 379 16.7 (15.7–17.6) 438 22.3 (21.3–23.2)
EPA (%) 405 1.5 (1.4–1.6) 491 1.7 (1.6–1.8)
DHA (%) 405 4.9 (4.8–5.1) 491 5.7 (5.6–5.8)
HDL-C (mmol/L) 402 1.5 (1.4–1.6) 490 1.8 (1.7–1.9)
LDL-C (mmol/L) 402 2.8 (2.7–2.9) 490 2.7 (2.6–2.8)
Blood lead (μmol/L) 405 0.27 (0.25–0.29) 491 0.21 (0.20–0.23)
Consumption (g/day)
Marine mammal fat 346 4.4 (3.4–5.4) 401 4.9 (3.7–6.1)
Marine mammal meat 347 25.9 (21.2–30.5) 404 18.5 (15.4–21.6)
Wild fish 347 59.8 (52.2–67.4) 404 51.1 (44.5–57.7)
No. of cigarettes/day (%)
0 100 27.2 (23.4–31.4) 96 21.6 (18.5–25.2)
1–10 83 24.5 (20.4–29.0) 174 40.6 (36.2–45.1)
11–24 113 32.4 (27.8–37.3) 122 27.8 (24.0–32.0)
≥ 25 58 15.9 (12.7–19.8) 42 10.0 (7.8–12.8)
Frequency of alcohol consumption (%)
Daily 26 7.5 (4.4–10.2) 34 8.3 (6.0–11.3)
Weekly 83 23.1 (19.3–27.3) 74 18.7 (15.5–22.3)
Monthly 82 24.0 (19.8–28.7) 95 21.9 (18.6–25.6)
Never or yearly 161 45.5 (40.6–50.4) 227 51.2 (47.2–55.2)
Statin intake (%)
Yes 34 7.8 (5.9–10.2) 36 7.1 (5.3–9.4)
No 371 92.2 (89.8–94.1) 455 92.9 (90.6–94.7)
Cardiovascular diseasea (%)
Yes 70 16.6 (13.7–19.9) 94 19.7 (16.7–23.0)
No 335 83.4 (80.1–86.3) 397 80.3 (77.0–83.3)
Diabetes (%)
Yes 12 3.0 (1.8–4.9) 20 3.88 (2.6–5.7)
No 393 97.0 (95.2–98.2) 455 96.1 (94.3–97.4)
Dyslipidemia (%)
Yes 35 8.0 (6.1–10.4) 36 7.1 (5.3–9.4)
No 370 92.0 (89.6–93.9) 455 92.9 (90.7–94.7)
CI, confidence interval. 
aIncludes all cardiovascular diseases except hypertension.Ayotte et al.
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adults between 18 and 74 years of age; the 
mean age of the group was 36.6 years. We 
noted a BMI value exceeding 30 kg/m2 in 
26.0% of men and 31.1% of women. More 
than two-thirds of the participants were cur-
rent smokers, and their average consumption 
was 15.7 cigarettes/day for men and 12.5 ciga-
rettes/day for women. The vast majority of 
men (92.8%) and women (84.3%) declared 
drinking alcohol. More than 90% of men and 
women declared consuming marine mam-
mal meat and wild fish, whereas about 70% 
reported eating marine mammal fat. Daily 
wild fish consumption was more than double 
that of marine mammal meat and exceeded 
by an order of magnitude the consumption of 
marine mammal fat. According to the medi-
cal files, about 8% of men and 7% of women 
had dyslipidemia and were taking hypo-
lipemic drugs (statins) at the time of the study. 
Cardiovascular diseases were affecting 17% of 
men and 20% of women, whereas only 3% of 
men and 4% of women had diabetes.
Figure 1A presents the frequency distri-
bution of plasma PON1 activity. The geo-
metric mean was 10.7 kU/L, with values 
ranging from 4.3 to 24.6 kU/L. Frequency 
distributions of blood mercury concentra-
tions (Figure 1B) and blood selenium concen-
trations (Figure 1C) were markedly skewed 
to the right. Geometric mean values were 
53.2 nmol/L (range, 0.4–720) and 3.8 μmol/L 
(range, 1.5–23.0) for blood mercury and blood 
selenium   concentrations, respectively.
We first tested crude correlations between 
PON1 activity and mercury and selenium 
concentrations. PON1 activity was positively 
correlated to both blood selenium (Pearson’s 
r = 0.14; p < 0.001) and mercury (r = 0.08; 
p = 0.024) concentrations. In addition, PON1 
activity was positively correlated with the sum 
of EPA and DHA content of erythrocyte 
membranes (r = 0.17; p < 0.001), HDL-C 
(r = 0.29; p < 0.001), LDL-C (r = 0.12; 
p < 0.001), and marine mammal fat consump-
tion (r = 0.10; p = 0.008). In bivariate analy-
ses (Table 2), women displayed higher PON1 
activity than did men (p < 0.001). The three 
SNPs of known functionality in the PON1 
gene were all significantly associated with 
PON1 activity (p < 0.001). Alcohol consump-
tion was positively associated with PON1 
activity (p = 0.046). Participants with diabetes 
had a lower mean PON1 activity than did 
those without the disease (p = 0.017).
We used multivariate models to examine 
the relation between PON1 activity and blood 
concentrations of mercury and selenium, 
while taking into account several potential 
confounders, including PON1 gene variants 
previously shown to influence PON1 activ-
ity or expression (Table 3). In a model that 
explained 31.4% of the variance in PON1 
activity (n = 651), blood selenium concen-
tration remained positively associated with 
PON1 activity (p < 0.001), whereas, in con-
trast with the bivariate analysis, blood mer-
cury concentration was inversely associated 
with the activity of the enzyme (p < 0.001). 
Also in contrast with the results of the bivari-
ate analysis, age was inversely associated with 
PON1 activity in the multivariate model 
(p < 0.001). Sex was not associated with 
PON1 activity, and we therefore excluded it 
from the final model. We obtained a simi-
lar model for the entire population sample 
(n = 896) after multiple imputation of geno-
types (data not shown).
Further adjustment of the multi  variate 
model for blood lead level, fat mass, or tradi-
tional food intakes did not modify the relation 
between blood mercury level and PON1 activ-
ity [see Supplemental Material, models 1–3 
(doi:10.1289/ehp.1003296)]. We tested the 
interaction terms between mercury and sele-
nium, mercury and n-3 PUFAs, and mercury 
and PON1 gene variants [see Supplemental 
Material,  models  4–6  (doi:10.1289/
ehp.1003296)]. None of these interaction 
terms were statistically significant (p > 0.1).
Figure 2 presents the relation between 
blood mercury concentrations (expressed 
in quartiles) and adjusted geometric mean 
PON1 activity. Mean activity values decreased 
in a concentration-dependent fashion with 
increasing blood mercury concentrations 
(p for trend < 0.001). The geometric mean 
activity corresponding to the highest blood 
mercury quartile (> 110 nmol/L; 9.8 kU/L) 
was 13% lower (p < 0.001) than that of the 
lowest blood mercury quartile (≤ 30 nmol/L; 
11.3 kU/L).
Discussion
In this cross-sectional study, we examined the 
relationship between blood mercury levels 
and plasma PON1 activity in a representative 
sample of the Inuit population of Nunavik, 
which has been shown to be highly exposed 
to MeHg mainly through their consump-
tion of marine mammal meat, kidney, and 
liver (Fontaine et al. 2008). After control-
ling for several potential confounding fac-
tors, we found that increasing blood mercury 
concentrations were inversely associated with 
the activity of this enzyme, which protects 
HDL and LDL from oxidation. Previous 
evidence for such a relationship had been 
obtained from in vitro studies in which liver 
microsomes were exposed to various concen-
trations of the organomercurial compound 
(Gonzalvo et al. 1997). To our knowledge, 
this is the first study to report an apparent 
inhibitory effect of MeHg exposure on PON1 
activity in a human population.
Although blood mercury levels showed a 
weak positive correlation with PON1 activi-
ties in bivariate analyses, a multivariate analy-
sis that included several covariates revealed a 
negative association of blood mercury levels 
with PON1 activities. This can be explained 
by the intercorrelations of age, blood sele-
nium concentrations, plasma HDL levels, 
and the proportion of EPA plus DHA in red 
blood cell membranes (data not shown), in 
addition to these variables being linked to 
blood mercury levels and PON1 activities. 
Despite these multiple intercorrelations, we 
avoided collinearity problems in multivariate 
models by centering and scaling continuous 
  explanatory variables.
We noted that in addition to blood mer-
cury concentrations, age was also inversely 
related to PON1 activity, as previously 
Figure 1. Frequency distributions of PON1 activity (A), blood mercury concentrations (B), and blood selenium concentrations (C) in Inuit adults from Nunavik, 2004. 
Abbreviations: CI, confidence interval; GM, geometric mean.
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reported by others (Cherki et al. 2007; Jarvik 
et al. 2002; Seres et al. 2004). The negative 
effect of age on PON1 activity has been attrib-
uted to a reduced number of sulfhydryl groups 
on the protein, because of an increase in oxida-
tive stress in the elderly (Jaouad et al. 2006).
The positive association between HDL-C 
and PON1 activity was expected because the 
enzyme circulates in the plasma associated 
with HDL. This relation has been reported in 
other studies pertaining to factors that influ-
ence the activity of the enzyme in healthy 
subjects (Boesch-Saadatmandi et al. 2010; 
Ferré et al. 2003). We also noted a positive 
influence of EPA plus DHA content of eryth-
rocyte membranes on PON1 activity. The fact 
that n-3 PUFA intake is significantly linked 
to PON1 activity in a multivariate model that 
included HDL-C as a covariate suggests that 
these fatty acids may increase PON1 activ-
ity independently of their known effect on 
HDL-C levels. Results from an experiment in 
which rats were fed a diet rich in n-3 PUFAs 
(13.8% of caloric intake) showed reduced 
serum PON1 activity compared with rats 
receiving a diet with a low n-3 PUFA content 
(2.8% of caloric intake) (Varatharajalu et al. 
2010). Although these results suggest that a 
high intake of n-3 PUFAs can promote oxi-
dation, this may not be the case for a lower 
intake such as that of the Inuit population.
Three PON1 gene variants that were pre-
viously shown to affect the arylesterase activ-
ity of the enzyme (Brophy et al. 2001) were 
also found to influence the activity measured 
by the hydrolysis rate of the fluorogenic sub-
strate in the present study (Table 3). Based on 
squared partial correlation coefficients (data 
not shown), the rs705379 polymorphism had 
the largest effect on PON1 activity, followed 
by rs662 and then rs854560. Brophy et al. 
(2001) reported that the rs854560 effect of 
lowered arylesterase activity was attributable 
largely to linkage disequilibrium with the 
rs705379 polymorphism.
We specifically tested the interaction 
between blood mercury concentration and the 
rs662 (PON1192) polymorphism because of 
results from an in vitro study indicating that 
metals, including mercury, might be more 
effective in inhibiting the PON1R192 isozyme 
(Cole et al. 2002; Costa et al. 2005; Gençer 
and Arslan 2009). However, we did not find 
support for such an allele-specific susceptibil-
ity to MeHg toxicity, because the mercury 
× rs662 interaction term was not statistically 
significant when entered in a multivariate 
model [see Supplemental Material, model 4 
(doi:10.1289/ehp.1003296)].
Results from biochemical studies sug-
gest that the free thiol group on the cysteine-
285 residue may be the molecular target of 
Table 3. Multiple linear regression modela of plasma PON1 activity (log kU/L) in Inuit adults, Nunavik, 2004.
Variable β-Coefficient 95% CI p-Value
Age (years) –0.047 –0.066 to –0.028 < 0.001
Blood mercury (nmol/L)b –0.063 –0.091 to –0.035 < 0.001
Blood selenium (μmol/L)c 0.067 0.045 to 0.088 < 0.001
HDL-C (mmol/L)b 0.077 0.061 to 0.094 < 0.001
EPA + DHA (%) 0.048 0.023 to 0.074 < 0.001
PON1 variants
rs662 (Q192R)
GG (CC) –0.189 –0.241 to –0.136 < 0.001
AG (CT) –0.101 –0.147 to –0.055 < 0.001
rs854560 (L55M)d
TT (MM) 0.096 0.038 to 0.153 0.001
rs705379 (–108C/T)
GG (QQ) 0.366 0.279 to 0.452 < 0.001
AG (QR) 0.230 0.142 to 0.317 < 0.001
CI, confidence interval.
aMultiple R2 = 0.314; n = 651. bLog-transformed variables. cInverse-transformed variable. dReference category is AT and AA.
Figure 2. Relation between blood mercury con-
centrations and PON1 activity in Inuit adults from 
Nunavik. Each bar represents the geometric mean 
± 95% confidence interval. Mean values were 
adjusted for age, blood selenium levels, plasma 
HDL-C concentrations, and PON1 genotypes (rs662, 
rs854560, rs705379). Different letters above the bars 
indicate mean values that are significantly different 
from one another.
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Table 2. Geometric mean (GM) PON1 activity (kU/L) according to selected characteristics of participants.
Characteristic n
GM (95% CI) 
PON1 activity p-Value
Sex < 0.001
Men 405 10.2 (9.9–10.4)
Women 491 11.1 (10.8–11.3)
No. of cigarettes/day 0.531
0 196 10.7 (10.3–11.2)
1–10 257 10.4 (10.1–10.8)
11–24 235 10.8 (10.5–11.1)
≥ 25 100 10.7 (10.2–11.2)
Frequency of alcohol consumption 0.046
Daily 60 11.5 (10.8–12.2)
Weekly 157 10.6 (10.3–11.1)
Monthly 177 10.7 (10.4–11.1)
Never of yearly 388 10.5 (10.2–10.8)
Variant and genotype
rs705379 (–108C/T) < 0.001
GG (CC) 419 11.4 (11.1–11.6)
AG (CT) 214 9.8 (9.5–10.1)
AA (TT) 26 7.5 (6.9–8.2)
rs662 (Q192R) < 0.001
GG (QQ) 224 9.9 (9.5–10.2)
AG (QR) 322 10.9 (10.6–11.2)
AA (RR) 108 11.8 (11.2–12.4)
rs854560 (L55M) < 0.001
TT (MM) 615 10.8 (10.6–11.0)
AT and AA (LM and LL) 41 9.3 (8.7–10.1)
Statin intake 0.572
Yes 70 10.4 (9.8–11.1)
No 826 10.6 (10.4–10.8)
Cardiovascular disease 0.663
Yes 164 10.5 (10.1–10.9)
No 732 10.6 (10.4–10.8)
Diabetes 0.017
Yes 32 9.5 (8.7–10.4)
No 864 10.6 (10.4–10.8)
Dyslipidemia 0.694
Yes 71 10.5 (9.8–11.1)
No 825 10.6 (10.4–10.8)
CI, confidence interval.Ayotte et al.
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mercurials (Debord et al. 2003; Gonzalvo 
et al. 1997). Although the cysteine-285 resi-
due does not seem essential for the enzyme 
activity (Sorenson et al. 1995), binding of 
MeHg to the thiol group could alter the active 
site of enzyme and in turn reduce its catalytic 
activity. This mechanism has been implicated 
in the inhibition of different enzymes by 
MeHg, such as thioredoxin (Carvalho et al. 
2008) and arylamine N-acetyl transferase-1 
(Ragunathan et al. 2010). Interestingly, we 
observed that blood selenium levels appeared 
to oppose the effect of blood mercury levels 
on plasma PON1 activity. Selenium is pres-
ent in the active site of several enzymes, such 
as thioredoxin reductase, which is involved 
in redox regulation (Carvalho et al. 2008), 
and glutathione peroxidase, which protects 
from oxidative stress (Rayman 2009). Further 
studies are needed to identify selenium species 
that are present in selenium-rich food items 
consumed by the Inuit (e.g., beluga skin) and 
to decipher the mechanism through which 
selenium intake might protect against MeHg-
induced toxicity in the Inuit population.
A strong point of the present study is its 
sampling design that allows a proper repre-
sentation of the Inuit population of Nunavik. 
Furthermore, to document the precision of 
the PON1 activity measurement, we included 
in each analytical batch a plasma sample that 
had been obtained from a volunteer at the 
beginning of the study, processed and stored 
frozen in the same conditions as the popu-
lation samples. Finally, we determined the 
genotypes for three SNPs that are known to 
affect the expression of PON1 or its catalytic 
activity. This allowed us to verify whether 
interactions between mercury exposure and 
PON1 gene variants that had been noted dur-
ing in vitro experiments could be observed in 
the Inuit population.
There is no consensus regarding the 
optimal substrate to measure PON1 activ-
ity in relation to cardiovascular diseases. 
Some authors measured the activity of the 
enzyme toward paraoxon (Ferré et al. 2003; 
Mackness et al. 2003), others used phenyl-
acetate (Jayakumari and Thejaseebai 2009), 
and still others measured the activity toward 
two substrates, usually paraoxon and diazoxon 
(Costa et al. 2005). We used a commercial 
kit, the EnzChek Paraoxonase Assay Kit from 
Invitrogen, to measure the PON1 activity in 
plasma samples of our participants. Recently, 
Yang et al. (2010) reported that PON1 activ-
ity, as measured by the same commercial 
kit, was associated with early structural and 
functional changes of arteries in a group of 
156 hypertensive patients. Furthermore, in 
the present study, polymorphisms that were 
previously shown to influence PON1 catalytic 
activity or expression also modified PON1 
activity, in the expected direction. We are 
looking forward to testing whether PON1 
activity as measured by this commercial kit 
will constitute a useful biomarker to pre-
dict the risk of cardiovascular disease in this 
popu  la  tion during the follow-up phase of the 
cohort study.
Conclusion
Results of this cross-sectional study suggest that 
MeHg exposure exerts an inhibitory effect on 
plasma PON1 activity. In addition to being a 
source of exposure to MeHg, marine foods that 
are part of the traditional Inuit diet are rich 
in selenium and n-3 PUFAs that may offset 
inhibitory effects of MeHg on PON1 activity. 
Dietary changes leading to a decrease in intake 
of these nutrients could lead to lower PON1 
activity and, in turn, increased risk of CHD. 
Follow-up of the participants is indicated in 
order to monitor dietary changes and possible 
related modifications in biomarkers of cardio-
vascular risk, including PON1 activity.
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